SCHOTT Pharma KGaA Past Earnings Performance
Past criteria checks 2/6
SCHOTT Pharma KGaA has been growing earnings at an average annual rate of 16.6%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 7.1% per year. SCHOTT Pharma KGaA's return on equity is 18.5%, and it has net margins of 14.7%.
Key information
16.6%
Earnings growth rate
16.5%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 7.1% |
Return on equity | 18.5% |
Net Margin | 14.7% |
Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How SCHOTT Pharma KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 916 | 135 | 125 | 28 |
31 Dec 23 | 906 | 158 | 124 | 27 |
30 Sep 23 | 899 | 152 | 123 | 27 |
30 Jun 23 | 873 | 143 | 123 | 24 |
30 Sep 22 | 821 | 125 | 111 | 24 |
30 Sep 21 | 649 | 101 | 92 | 22 |
30 Sep 20 | 584 | 77 | 90 | 24 |
Quality Earnings: 1SXP has high quality earnings.
Growing Profit Margin: 1SXP's current net profit margins (14.7%) are lower than last year (16%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1SXP's earnings have grown by 16.6% per year over the past 5 years.
Accelerating Growth: 1SXP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1SXP had negative earnings growth (-1.7%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.7%).
Return on Equity
High ROE: 1SXP's Return on Equity (18.5%) is considered low.